After obtaining her PhD in molecular biology of cancer at the University of Leiden, Dr. Lucy Peltenburg worked as a post-doc at the Biology department at the University of California San Diego. She returned to the Leiden University Medical Center in the Netherlands to become assistant professor, working on the molecular mechanism of programmed cell death in tumors. In 2005, she joined the biotech company Crucell (now Janssen Vaccines), eventually becoming the head of the strategic planning department. From 2010, she served as Head of R&D Operations at Prosensa Therapeutics, which focused on developing RNA drugs to treat Duchenne muscular dystrophy. In this position she developed an effective R&D planning methodology, which addresses resourcing, financial and scenario planning requirements in one application. After the acquisition of Prosensa by BioMarin Pharmaceutical in 2015, she worked as Executive Director in the US-based Development Sciences and Portfolio Product Development departments. In 2018, she founded Ganttenburg Consultancy, a consulting firm that specializes in supporting strategic financial planning and drug development operations in the life sciences area. Through Ganttenburg, she acts as lead operational consultant and strategic advisor to multiple start-up and scale-up R&D companies, with diverse technologies and therapeutic areas. Dr. Lucy Peltenburg brings over 18 years of experience in development strategy and operational finance from numerous senior positions. She combines scientific knowledge with financial and business experience.